Boston Scientific Corporation (LON:0HOY)
102.53
-0.58 (-0.56%)
At close: May 12, 2025
Boston Scientific Revenue
Boston Scientific had revenue of $4.66B USD in the quarter ending March 31, 2025, with 20.93% growth. This brings the company's revenue in the last twelve months to $17.55B, up 19.36% year-over-year. In the year 2024, Boston Scientific had annual revenue of $16.75B with 17.61% growth.
Revenue (ttm)
$17.55B
Revenue Growth
+19.36%
P/S Ratio
8.48
Revenue / Employee
$331.21K
Employees
53,000
Market Cap
115.21B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.75B | 2.51B | 17.61% |
Dec 31, 2023 | 14.24B | 1.56B | 12.29% |
Dec 31, 2022 | 12.68B | 794.00M | 6.68% |
Dec 31, 2021 | 11.89B | 1.98B | 19.92% |
Dec 31, 2020 | 9.91B | -822.00M | -7.66% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
Boston Scientific News
- 5 days ago - Boston Scientific Stock Flirts With A Buy Point, Once Again - Investor's Business Daily
- 11 days ago - $100 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today - Benzinga
- 12 days ago - Boston Scientific announces upcoming investor conference schedule - PRNewsWire
- 13 days ago - Baron Health Care Fund Q1 2025 Top Contributors And Detractors - Seeking Alpha
- 18 days ago - Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints - PRNewsWire
- 18 days ago - Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results - Benzinga
- 18 days ago - Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results - Benzinga
- 18 days ago - IBD Stock Of The Day, Boston Scientific, A 'Top Decile' Player, Is Eyeing Two Entries - Investor's Business Daily